MacroGenics, Inc.

MGNX ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011
Operating Activities
Net Income $-19.6M $-58.5M $-20.1M $-38.3M $-261.0K $8.4M $6.7M
Depreciation & Amortization $7.2M $7.6M $2.9M $1.8M $1.2M $1.0M $1.1M
Depreciation $7.0M $6.8M $3.2M $1.8M $1.2M $960.0K $1.1M
Amortization — — — — — — —
Stock-Based Compensation $14.7M $12.2M $7.8M $3.2M $862.0K $838.0K $2.3M
Net Cash from Operating Activities $14.4M $-43.7M $-13.7M $-32.8M $-14.2M $-6.6M $6.8M
Investing Activities
Capital Expenditures $29.4M $11.4M $9.2M $3.6M $3.0M $940.0K $500.2K
Business Acquisitions — — — — — — —
Net Cash from Investing Activities $77.9M — — — $-3.0M $-940.0K $-500.2K
Financing Activities
Dividends Paid — — — — — — —
Stock Repurchases — — — — — — —
Net Cash from Financing Activities $35.3M — — — $85.9M $46.8K $12.1M
Net Change in Cash $127.6M $-112.1M $38.6M $41.1M $68.7M $-7.5M $18.3M
Free Cash Flow $-15.0M $-55.1M $-22.9M $-36.3M $-17.1M $-7.5M $6.3M
← Newer Page 2 of 2 Older →